Aiolos Bio launches with $245M Series A, chasing one of asthma’s hottest targets
Two Genentech vets have landed one of biotech’s largest Series A rounds of 2023 as they launch Aiolos Bio to advance an asthma drug in-licensed from China.
Aiolos Bio on Tuesday announced a $245 million round, which ranks as one of the industry’s largest Series A raises in 2023. The startup expects to begin a Phase II asthma study next year for its sole drug candidate, an anti-TSLP antibody.
Aiolos CEO Khurem Farooq and fellow co-founder Anthony Adamis previously worked side-by-side at Genentech, respectively overseeing the commercial and development teams for the biotech’s immunology and ophthalmology work. Farooq most recently ran Gyroscope Therapeutics, which Novartis agreed to acquire in December 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.